Indivior PLC (IZQVF) は上場企業です ヘルスケア セクターの Drug Manufacturers - Specialty & Generic 業界で事業展開. 本社所在地は North Chesterfield, VA, アメリカ. 現CEOは Mark Crossley.
IZQVF を有する IPO日 2014-12-26, 1,000 名の正社員, に上場 Other OTC, 時価総額 $2.89B.
Indivior PLC is a specialty pharmaceutical company that develops, manufactures, and markets buprenorphine-based prescription medications for treating opioid dependence and related disorders. The company's primary products include SUBLOCADE, an injectable formulation, and SUBOXONE, available in sublingual film and tablet forms, alongside legacy medications such as Temgesic and Buprenex. With operations spanning approximately 40 countries worldwide, Indivior focuses on addressing opioid use disorder, addiction, and co-occurring conditions through its product pipeline. Headquartered in North Chesterfield, Virginia, the company was established in 2014 and maintains research collaborations to advance its therapeutic offerings.
